UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 31

Sortiert nach

Phase I study of pegylated liposomal doxorubicin in combination with bortezomib for Japanese patients with relapsed or refractory multiple myeloma

International journal of hematology, 2015-06, Vol.101 (6), p.578-584

2015

Link zum Volltext

Verfügbarkeit prüfen

Isatuximab monotherapy in relapsed/refractory multiple myeloma: A Japanese, multicenter, phase 1/2, safety and efficacy study

Cancer science, 2020-12, Vol.111 (12), p.4526-4539

2020

Link zum Volltext

Verfügbarkeit prüfen

Isatuximab plus pomalidomide and dexamethasone in elderly patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis

Haematologica (Roma), 2021-04, Vol.106 (4), p.1182-1187

2021

Link zum Volltext

Verfügbarkeit prüfen

Daratumumab therapy for relapsed or refractory multiple myeloma: a single-center retrospective study

International journal of clinical oncology, 2020-12, Vol.25 (12), p.2151-2157

2020

Link zum Volltext

Verfügbarkeit prüfen

Pomalidomide alone or in combination with dexamethasone in Japanese patients with refractory or relapsed and refractory multiple myeloma

Cancer science, 2015-11, Vol.106 (11), p.1561-1567

2015

Link zum Volltext

Verfügbarkeit prüfen

Propensity-score matched analysis of the efficacy of maintenance/continuous therapy in newly diagnosed patients with multiple myeloma: a multicenter retrospective collaborative study of the Japanese Society of Myeloma

Journal of cancer research and clinical oncology, 2022, Vol.148 (1), p.191-203

2022

Link zum Volltext

Verfügbarkeit prüfen

Alternating bortezomib-dexamethasone and lenalidomide-dexamethasone in patients with newly diagnosed multiple myeloma aged over 75 years

Nagoya journal of medical science, 2022-02, Vol.84 (1), p.80-90

2022

Link zum Volltext

Verfügbarkeit prüfen

Carfilzomib monotherapy in Japanese patients with relapsed or refractory multiple myeloma: A phase 1/2 study

Cancer science, 2019-09, Vol.110 (9), p.2924-2932

2019

Link zum Volltext

Verfügbarkeit prüfen

Carfilzomib, lenalidomide and dexamethasone in patients with heavily pretreated multiple myeloma: A phase 1 study in Japan

Cancer science, 2017-03, Vol.108 (3), p.461-468

2017

Link zum Volltext

Verfügbarkeit prüfen

Report of phase I and II trials of melphalan, prednisolone, and thalidomide triplet combination therapy versus melphalan and prednisolone doublet combination therapy in Japanese patients with newly diagnosed multiple myeloma ineligible for autologous stem cell transplantation

International journal of hematology, 2019-10, Vol.110 (4), p.447-457

2019

Link zum Volltext

Verfügbarkeit prüfen

Phase II Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Over 75 Years Old with Alternating Bortezomib/dexamethasone and Lenalidomide/dexamethasone: the MARBLE Trial

Acta medica Okayama, 2019-12, Vol.73 (6), p.547-552

2019

Link zum Volltext

Verfügbarkeit prüfen

Continuous lenalidomide treatment after bortezomib-melphalan-prednisolone therapy for newly diagnosed multiple myeloma

Annals of hematology, 2020-05, Vol.99 (5), p.1063-1072

2020

Link zum Volltext

Verfügbarkeit prüfen

Changing trends in prognostic factors for patients with multiple myeloma after autologous stem cell transplantation during the immunomodulator drug/proteasome inhibitor era

Cancer science, 2015-02, Vol.106 (2), p.179-185

2015

Link zum Volltext

Verfügbarkeit prüfen

Bortezomib, doxorubicin and intermediate-dose dexamethasone (iPAD) therapy for relapsed or refractory multiple myeloma: a multicenter phase 2 study

International journal of hematology, 2013-08, Vol.98 (2), p.179-185

2013

Link zum Volltext

Verfügbarkeit prüfen

Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study

The Lancet (British edition), 2019-12, Vol.394 (10214), p.2096-2107

2019

Link zum Volltext

Verfügbarkeit prüfen

A phase I study of bortezomib in combination with doxorubicin and intermediate-dose dexamethasone (iPAD therapy) for relapsed or refractory multiple myeloma

International journal of hematology, 2010-10, Vol.92 (3), p.503-509

2010

Link zum Volltext

Verfügbarkeit prüfen

Induction therapy of transplant-eligible patients in multiple myeloma

Nihon rinshō, 2015-01, Vol.73 (1), p.90

2015

Link zum Volltext

Verfügbarkeit prüfen

Subgroup analysis of ICARIA‐MM study in relapsed/refractory multiple myeloma patients with high‐risk cytogenetics

British journal of haematology, 2021-07, Vol.194 (1), p.120-131

2021

Link zum Volltext

Verfügbarkeit prüfen

Efficacy of novel agents for patients with newly diagnosed symptomatic multiple myeloma

Rinshō ketsueki, 2012-06, Vol.53 (6), p.580

Sunami, Kazutaka

2012

Link zum Volltext

Verfügbarkeit prüfen

Safety and management of adverse events of ixazomib/lenalidomide/dexamethasone therapy in Japanese patients with relapsed/refractory multiple myeloma

Rinshō ketsueki, 2018, Vol.59 (11), p.2399

2018

Link zum Volltext

Verfügbarkeit prüfen

A nationwide survey on central nervous system multiple myeloma in Japan: analysis of prognostic and treatment factors that impact survival

British journal of haematology, 2021-10, Vol.195 (2), p.217-229

2021

Link zum Volltext

Verfügbarkeit prüfen

Isatuximab plus pomalidomide and dexamethasone in elderly patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis

Haematologica (Roma), 2022-03, Vol.107 (3), p.774-775

2022

Link zum Volltext

Verfügbarkeit prüfen

A phase 1/2 study of carfilzomib in Japanese patients with relapsed and/or refractory multiple myeloma

British journal of haematology, 2016-03, Vol.172 (5), p.745-756

2016

Link zum Volltext

Verfügbarkeit prüfen

Pembrolizumab plus lenalidomide and dexamethasone in treatment-naive multiple myeloma (KEYNOTE-185): subgroup analysis in Japanese patients

International journal of hematology, 2020-11, Vol.112 (5), p.640-649

2020

Link zum Volltext

Verfügbarkeit prüfen

Reduced frequency treatment with bortezomib plus dexamethasone for elderly patients with relapsed and/or refractory multiple myeloma: a phase 2 study of the Japanese Myeloma Study Group (JMSG-0902)

Annals of hematology, 2016-05, Vol.95 (6), p.921-929

2016

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 31

Suche als RSS-Feed

Aktive Filter

ThemaMultiple Myeloma - Drug Therapy

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(27)
Mit Volltextzugriff
(28)

Publikationsform

Artikel
(31)

Sprache

Englisch
(28)
Japanisch
(5)

Erscheinungsjahr

n.n

Thema

Humans
(31)
Aged
(28)
Life Sciences & Biomedicine
(27)
Science & Technology
(27)
Multiple Myeloma
(26)
Male
(24)
Female
(23)
Middle Aged
(21)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(19)
Hematology
(18)
Aged, 80 And Over
(17)
Dexamethasone
(17)
Oncology
(16)
Antineoplastic Combined Chemotherapy Protocols - Adverse Effects
(13)
Multiple Myeloma - Mortality
(13)
Adult
(11)
Bortezomib
(11)
Patients
(11)
Dexamethasone - Administration & Dosage
(10)

14 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Phase I study of pegylated liposomal doxorubicin in combination with bortezomib for Japanese patients with relapsed or refractory multiple myeloma

Isatuximab monotherapy in relapsed/refractory multiple myeloma: A Japanese, multicenter, phase 1/2, safety and efficacy study

Isatuximab plus pomalidomide and dexamethasone in elderly patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis

Daratumumab therapy for relapsed or refractory multiple myeloma: a single-center retrospective study

Pomalidomide alone or in combination with dexamethasone in Japanese patients with refractory or relapsed and refractory multiple myeloma

Propensity-score matched analysis of the efficacy of maintenance/continuous therapy in newly diagnosed patients with multiple myeloma: a multicenter retrospective collaborative study of the Japanese Society of Myeloma

Alternating bortezomib-dexamethasone and lenalidomide-dexamethasone in patients with newly diagnosed multiple myeloma aged over 75 years

Carfilzomib monotherapy in Japanese patients with relapsed or refractory multiple myeloma: A phase 1/2 study

Carfilzomib, lenalidomide and dexamethasone in patients with heavily pretreated multiple myeloma: A phase 1 study in Japan

Report of phase I and II trials of melphalan, prednisolone, and thalidomide triplet combination therapy versus melphalan and prednisolone doublet combination therapy in Japanese patients with newly diagnosed multiple myeloma ineligible for autologous stem cell transplantation

Phase II Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Over 75 Years Old with Alternating Bortezomib/dexamethasone and Lenalidomide/dexamethasone: the MARBLE Trial

Continuous lenalidomide treatment after bortezomib-melphalan-prednisolone therapy for newly diagnosed multiple myeloma

Changing trends in prognostic factors for patients with multiple myeloma after autologous stem cell transplantation during the immunomodulator drug/proteasome inhibitor era

Bortezomib, doxorubicin and intermediate-dose dexamethasone (iPAD) therapy for relapsed or refractory multiple myeloma: a multicenter phase 2 study

Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study

A phase I study of bortezomib in combination with doxorubicin and intermediate-dose dexamethasone (iPAD therapy) for relapsed or refractory multiple myeloma

Induction therapy of transplant-eligible patients in multiple myeloma

Subgroup analysis of ICARIA‐MM study in relapsed/refractory multiple myeloma patients with high‐risk cytogenetics

Efficacy of novel agents for patients with newly diagnosed symptomatic multiple myeloma

Safety and management of adverse events of ixazomib/lenalidomide/dexamethasone therapy in Japanese patients with relapsed/refractory multiple myeloma

A nationwide survey on central nervous system multiple myeloma in Japan: analysis of prognostic and treatment factors that impact survival

Isatuximab plus pomalidomide and dexamethasone in elderly patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis

A phase 1/2 study of carfilzomib in Japanese patients with relapsed and/or refractory multiple myeloma

Pembrolizumab plus lenalidomide and dexamethasone in treatment-naive multiple myeloma (KEYNOTE-185): subgroup analysis in Japanese patients

Reduced frequency treatment with bortezomib plus dexamethasone for elderly patients with relapsed and/or refractory multiple myeloma: a phase 2 study of the Japanese Myeloma Study Group (JMSG-0902)

Aktive Filter

Suchergebnisse filtern